EMA Authorised: Aripiprazole Sandoz (aripiprazole) — Sandoz GmbH

View source ↗

Summary

The European Medicines Agency authorised Aripiprazole Sandoz (aripiprazole) by Sandoz GmbH for treating schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Aripiprazole Sandoz (aripiprazole)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Sandoz GmbH. Decision date: 10/04/2026